{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:34:22Z","timestamp":1762868062063,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Fonds de recherche Qu\u00e9bec-Sant\u00e9"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11255-020-02384-3","type":"journal-article","created":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T17:02:32Z","timestamp":1580576552000},"page":"343-349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention"],"prefix":"10.1007","volume":"52","author":[{"given":"Gabrielle","family":"C\u00f4t\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Asselin-Thompstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Mac-Way","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Ren\u00e9 de Cotret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Desmeules","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7628-5757","authenticated-orcid":false,"given":"Mohsen","family":"Agharazii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,1]]},"reference":[{"issue":"Suppl 4","key":"2384_CR1","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, Areste N, de la Torre RA, Caskey F, Couchoud C, Finne P, Heaf J, Hoitsma A, de Meester J, Pascual J, Postorino M, Ravani P, Zurriaga O, Jager KJ, Gansevoort RT, Registry E-E, Euro CC (2014) Renal replacement therapy for autosomal dominant polycystic kidney disease (adpkd) in Europe: prevalence and survival\u2014an analysis of data from the era-edta registry. Nephrol Dial Transplant 29(Suppl 4):iv15\u2013iv25","journal-title":"Nephrol Dial Transplant"},{"key":"2384_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0092-8674(94)90362-X","volume":"78","author":"The European Polycystic Kidney Disease Consortium","year":"1994","unstructured":"The European Polycystic Kidney Disease Consortium (1994) The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 78:725","journal-title":"Cell"},{"key":"2384_CR3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","volume":"272","author":"T Mochizuki","year":"1996","unstructured":"Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJM, Somlo S (1996) Pkd2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272:1339\u20131342","journal-title":"Science"},{"key":"2384_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/ki.2009.128","volume":"76","author":"VE Torres","year":"2009","unstructured":"Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76:149\u2013168","journal-title":"Kidney Int"},{"key":"2384_CR5","doi-asserted-by":"publisher","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","volume":"301","author":"GA Reif","year":"2011","unstructured":"Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP (2011) Tolvaptan inhibits erk-dependent cell proliferation, cl(-) secretion, and in vitro cyst growth of human adpkd cells stimulated by vasopressin. Am J Physiol Renal Physiol 301:F1005\u20131013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2384_CR6","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, Investigators TT (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407\u20132418","journal-title":"N Engl J Med"},{"key":"2384_CR7","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O, Investigators RT (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377:1930\u20131942","journal-title":"N Engl J Med"},{"key":"2384_CR8","doi-asserted-by":"crossref","first-page":"205435811880158","DOI":"10.1177\/2054358118801589","volume":"5","author":"S Soroka","year":"2018","unstructured":"Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R, McFarlane P, Pandeya S, Tam P, Bichet DG (2018) Updated Canadian expert consensus on assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease. Can J Kidney Health Dis 5:2054358118801589","journal-title":"Can J Kidney Health Dis"},{"key":"2384_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","volume":"73","author":"BJ Kramers","year":"2019","unstructured":"Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT (2019) Determinants of urine volume in adpkd patients using the vasopressin v2 receptor antagonist tolvaptan. Am J Kidney Dis 73:354\u2013362","journal-title":"Am J Kidney Dis"},{"key":"2384_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE, Investigators C (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26:160\u2013172","journal-title":"J Am Soc Nephrol"},{"key":"2384_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"2384_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","volume":"1","author":"MV Irazabal","year":"2016","unstructured":"Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Chapman AB, Devuyst O, Higashihara E, Harris PC, Zhou W, Ouyang J, Czerwiec FS, Torres VE (2016) Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the tempo 3:4 clinical trial. Kidney Int Rep 1:213\u2013220","journal-title":"Kidney Int Rep"},{"key":"2384_CR13","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2215\/CJN.03530411","volume":"6","author":"E Higashihara","year":"2011","unstructured":"Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS (2011) Tempoformula, Study I. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 6:2499\u20132507","journal-title":"Clin J Am Soc Nephrol"},{"key":"2384_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ki.2011.119","volume":"80","author":"MV Irazabal","year":"2011","unstructured":"Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS (2011) Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 80:295\u2013301","journal-title":"Kidney Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02384-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-020-02384-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02384-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T00:09:34Z","timestamp":1612051774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-020-02384-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2384"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02384-3","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"type":"print","value":"0301-1623"},{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"30 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FM has received conference honoraria from Amgen and Sanofi, and received consultative honoraria from Otsuka; CL and MA have received consultative honoraria from Otsuka; PRC has received honoraria for consultation and CMEs from Otsuka Canada.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}